» Articles » PMID: 27431575

PiR-651 Promotes Tumor Formation in Non-small Cell Lung Carcinoma Through the Upregulation of Cyclin D1 and CDK4

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2016 Jul 20
PMID 27431575
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Piwi-interacting RNAs (piRNAs or piRs) are a novel class of non-coding RNAs that participate in germline development by silencing transposable elements and regulating gene expression. To date, the association between piRNAs and non‑small cell lung carcinoma (NSCLC) has not yet been elucidated. In the present study, we have demonstrated that a significant increase in piR-651 expression occurs in NSCLC. Furthermore, the abnormal expression of piR-651 was associated with cancer progression in the patients with NSCLC. The upregulation of piR-651 in A549 cells caused a significant increase in cell viability and metastasis. The percentage of arrested cells in the G0/G1 phase was lower after piR-651 overexpression compared with the controls. We also examined the expression of oncogenes and cancer suppressor genes following piR-651 overexpression in NSCLC cells. Only the expression levels of cyclin D1 and CDK4 significantly correlated with piR-651 expression both in vivo and in vitro. Furthermore, by injecting nude mice with A549 cells transfected with piR-651 plasmids to establish a xenograft model, we demonstrated that there was a correlation between piR-651 overexpression and tumor growth, which was mediated by cyclin D1 and CDK4. These findings strongly support the notion that piR-651 induces NSCLC progression through the cyclin D1 and CDK4 pathway and it may have applications as a potential diagnostic indicator and therapeutic target in the management of NSCLC.

Citing Articles

Development and validation of a novel artificial intelligence algorithm for precise prediction the postoperative prognosis of esophageal squamous cell carcinoma.

Wang Z, Xiao Z, Zhang T, Lu M, Li H, Cao J BMC Cancer. 2025; 25(1):134.

PMID: 39849452 PMC: 11756118. DOI: 10.1186/s12885-025-13520-6.


Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.

Zhan Y, Tian F, Fan W, Li X, Wang X, Zhang H Adv Sci (Weinh). 2024; 12(6):e2414100.

PMID: 39692168 PMC: 11809383. DOI: 10.1002/advs.202414100.


piRNA in Machine-Learning-Based Diagnostics of Colorectal Cancer.

Li S, Kouznetsova V, Kesari S, Tsigelny I Molecules. 2024; 29(18).

PMID: 39339306 PMC: 11434383. DOI: 10.3390/molecules29184311.


piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.

Yan Y, Tian D, Zhao B, Li Z, Huang Z, Li K Technol Cancer Res Treat. 2024; 23:15330338241249692.

PMID: 38706262 PMC: 11072069. DOI: 10.1177/15330338241249692.


The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis).

Taghizadeh M, Jafari-Koshki T, Jafarlou V, Raeisi M, Alizadeh L, Roosta Y BMC Cancer. 2024; 24(1):484.

PMID: 38627675 PMC: 11022431. DOI: 10.1186/s12885-024-12180-2.